Lepu Biopharma Co., Ltd. (HKG:2157)

Market Cap	7.64B -39.6%
Revenue (ttm)	1.14B +41.5%
Net Income	285.17M
EPS	0.16
Shares Out	1.80B
PE Ratio	26.76
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,264,000
Open	4.075
Previous Close	4.120
Day's Range	4.055 - 4.325
52-Week Range	3.550 - 8.110
Beta	-0.42
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 646
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2157

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error